Literature DB >> 23265700

Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years.

Tanja Cufer1, Tanja Ovcaricek, Mary E R O'Brien.   

Abstract

The standard palliative treatment for advanced stage NSCLC remains a platinum doublet but by tailoring chemotherapy according to tumour histology the results can be improved through using pemetrexed-containing schemas in non-squamous-cell disease. In addition, maintenance chemotherapy appears to be effective in patients achieving clinical benefit by induction therapy. Targeted therapy based on the presence of activating epidermal growth factor receptor (EGFR) activating mutations or EML4-ALK gene rearrangement is becoming standard practice with high median survival rates, up to 30 months. There are still numerous other molecular targeted drugs in development. This review presents the most recent relevant progress in systemic anti-cancer therapy of advanced NSCLC in the past 5 years and delineates today's new treatment options.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23265700     DOI： 10.1016/j.ejca.2012.11.021

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  41 in total

1.  Analysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years old.

Authors:  Ting Ye; Yunjian Pan; Rui Wang; Haichuan Hu; Yang Zhang; Hang Li; Lei Wang; Yihua Sun; Haiquan Chen
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis.

Authors:  Yaxiong Zhang; Wenfeng Fang; Yue Yan; Mengyao Wang; Shiyang Kang; Jin Sheng; Jianhua Zhan; Nan Chen; Shaodong Hong; Yunpeng Yang; Yuxiang Ma; Dacheng He; Tao Qin; Ting Zhou; Yanna Tang; Xiaobo He; Wenhua Liang; Li Zhang
Journal:  Med Oncol       Date:  2015-02-08       Impact factor: 3.064

3.  A reevaluation of CD22 expression in human lung cancer.

Authors:  Laurentiu M Pop; Stephen Barman; Chunli Shao; Jonathan C Poe; Guglielmo M Venturi; John M Shelton; Iliodora V Pop; David E Gerber; Luc Girard; Xiao-yun Liu; Carmen Behrens; Jaime Rodriguez-Canales; Hui Liu; Ignacio I Wistuba; James A Richardson; John D Minna; Thomas F Tedder; Ellen S Vitetta
Journal:  Cancer Res       Date:  2014-01-01       Impact factor: 12.701

4.  Analysis of sebum lipid composition and the development of acneiform rash before and after administration of egfr inhibitor.

Authors:  T Nakahara; Y Moroi; K Takayama; Y Nakanishi; M Furue
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

5.  A clinical-radiomics nomogram for the preoperative prediction of lung metastasis in colorectal cancer patients with indeterminate pulmonary nodules.

Authors:  TingDan Hu; ShengPing Wang; Lv Huang; JiaZhou Wang; DeBing Shi; Yuan Li; Tong Tong; Weijun Peng
Journal:  Eur Radiol       Date:  2018-06-12       Impact factor: 5.315

6.  Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.

Authors:  J Garde-Noguera; P Martin-Martorell; M De Julián; J Perez-Altozano; C Salvador-Coloma; J García-Sanchez; A Insa-Molla; M Martín; X Mielgo-Rubio; S Marin-Liebana; A Blasco-Cordellat; S Blasco-Molla; R Gironés; D Marquez-Medina; F Aparisi; M C Bas Cerda; S Macia-Escalante; A Sánchez; O Juan-Vidal
Journal:  Clin Transl Oncol       Date:  2018-01-24       Impact factor: 3.405

7.  Epithelial-mesenchymal transition in patients of pulmonary adenocarcinoma: correlation with cancer stem cell markers and prognosis.

Authors:  Woo Jung Sung; Ki-Sung Park; Sang Gyu Kwak; Dae-Sung Hyun; Jae Seok Jang; Kwan-Kyu Park
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

8.  Expression and potential mechanism of metabolism-related genes and CRLS1 in non-small cell lung cancer.

Authors:  Hai-Ming Feng; Ye Zhao; Jian-Ping Zhang; Jian-Hua Zhang; Peng Jiang; Bin Li; Cheng Wang
Journal:  Oncol Lett       Date:  2017-12-12       Impact factor: 2.967

9.  Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent.

Authors:  Ashish Saxena; Bryan J Schneider; Paul J Christos; Lauren F Audibert; Jennifer M Cagney; Ronald J Scheff
Journal:  Med Oncol       Date:  2016-01-09       Impact factor: 3.064

10.  FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.

Authors:  Hyun Woo Chung; Kye Young Lee; Hee Joung Kim; Wan Seop Kim; Young So
Journal:  J Cancer Res Clin Oncol       Date:  2013-11-06       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.